The company is planning to commercially launch these connected insulin pens in the first quarter of next year across limited markets. The availability will then be expanded to more than 50 countries.
Over time, NovoPen 6 and NovoPen Echo Plus will replace NovoPen 5 and NovoPen Echo in regions where the devices are currently marketed.
As part of one of the agreements, Novo Nordisk will integrate dosing data from connected insulin pens with IBM Watson Health and Glooko’s open ecosystems and diabetes management solutions.
The deal with Roche will also see similar work, where Novo Nordisk insulin data will be synched with Roche’s diabetes management platforms, such as mySugr and Accu-Chek Smart Pix.
Such data integration is expected to improve quality of care and enable sustainable healthcare systems. Eventually, Novo Nordisk plans to integrate its insulin dosing data with Dexcom continuous glucose monitoring (CGM) data.
Novo Nordisk Commercial Strategy & Corporate Affairs executive vice-president Camilla Sylvest said: “Our non-exclusive partnership strategy allows us to integrate with the various digital platforms that people are already using to help manage their diabetes.
“We firmly believe that this will help more people realise the full benefit of our innovative medicines and begin to ease the mental burden of diabetes treatment for those individuals.”
Besides the connected insulin pens launch, the company intends to provide connectivity for its disposable, pre-filled injection pens next year.
Novo Nordisk long-term strategy involves enhanced access to the connected pens and offering personalised treatment guidance solutions for people living with diabetes.